NCT02290002View on ClinicalTrials.gov

Calcium Dobesilate Versus Coasting for Prevention of Ovarian Hyperstimulation Syndrome

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Infertility
Interventions
DRUG

Calcium Dobesilate

1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days

OTHER

coasting

In group B, coasting (withholding gonadotrophins while maintaining pituitary suppression) for 3 days then either giving triggering or cycle cancellation is done

Trial Locations (1)

13518

Benha univesity hospital, Banhā

All Listed Sponsors
lead

khalid abd aziz mohamed

OTHER

NCT02290002 - Calcium Dobesilate Versus Coasting for Prevention of Ovarian Hyperstimulation Syndrome | Biotech Hunter | Biotech Hunter